Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation-Reference-Cited by-同舟云学术

Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation

Published:2018-07-11 Issue:1 Volume:12 Page:63-70
ISSN:1865-7257
Container-title:Clinical Journal of Gastroenterology
language:en
Short-container-title:Clin J Gastroenterol

Author:

Orita Noriaki,Shimakami Tetsuro^ORCID,Sunagozaka Hajime,Horii Rika,Nio Kouki,Terashima Tekeshi,Iida Noriho,Kitahara Masaaki,Takatori Hajime,Kawaguchi Kazunori,Kitamura Kazuya,Arai Kuniaki,Yamashita Taro,Sakai Yoshio,Yamashita Tatsuya,Mizukoshi Eishiro,Honda Masao,Kaneko Shuichi

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

http://link.springer.com/article/10.1007/s12328-018-0884-y/fulltext.html

Reference26 articles.

1. Akamatsu N, Sugawara Y, Kokudo N, et al. Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int. 2014;27:767–74.

2. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 2004;10:1240–47.

3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.

4. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–87.

5. Tanaka T, Sugawara Y, Akamatsu N, et al. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci. 2015;22:144–50.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug–Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir–Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis;Therapeutic Drug Monitoring;2022-06

2. Ritonavir-boosted antiretroviral therapy precipitating tacrolimus toxicity in a renal transplant patient: is it time for a priori tacrolimus dosage reduction?;AIDS;2021-10-01

3. High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use;JGH Open;2020-06-23

4. Multiple drugs interaction;Reactions Weekly;2019-03